Drug manufacturer Alexion has announced positive topline results of a phase 3 study that determined that ALXN1210, a long-acting C5 complement inhibitor, can be safely and effectively switched among patients with paroxysmal nocturnal hemoglobinuria currently being treated with the shorter-acting eculizumab (Soliris).
Drug manufacturer Alexion has announced positive topline results of a phase 3 study that determined that ALXN1210, a long-acting C5 complement inhibitor, can be safely and effectively switched among patients with paroxysmal nocturnal hemoglobinuria (PNH) currently being treated with the shorter-acting eculizumab (Soliris).
PNH is a rare blood disorder that causes uncontrolled activation of the complement system and results in hemolysis, or the destruction of red blood cells. ALXN1210, like the earlier eculizumab counterpart, works to stop the destruction of red blood cells and prevent PNH from causing clots and organ damage. Significantly, the difference between the 2 drugs is that ALXN1210 is a long-acting inhibitor that only needs to be administered once every 8 weeks. Conversely, patients receiving eculizumab undergo intravenous infusions every 2 weeks.
The study, conducted among 195 adults with PNH in a randomized open-label trial, demonstrated non-inferiority of ALXN1210 to eculizumab in patients with PNH who are stable on eculizumab based on the primary endpoint of change in lactate dehydrogenase (LDH) levels.
Notably, the study also found non-inferiority on all 4 key secondary endpoints: proportion of patients with breakthrough hemolysis, change from baseline in quality of life as determined via the Functional Assessment of Chronic Illness Therapy Fatigue Scale, proportion of patients avoiding transfusion, and the proportion of patients with stable hemoglobin levels. LDH levels fell just shy of statistical superiority to eculizumab.
“The way I look at it, we don’t need the superiority claim to be successful for a fast conversion. We have a strong, differentiated clinical profile, a robust data package,” said Alexion’s CEO, Ludwig Hantson on an investor call, as reported by FierceBiotech.
In addition, the success of this phase 3 trial has positioned Alexion to seek regulatory approval, and potentially stave off market competition from a biosimilar version of eculizumab; currently, drug maker Amgen is developing a biosimilar candidate for the high-cost biologic that is also approved to treat myasthenia gravis.
However, analysts have found that despite this new innovation, payers are still looking to keep the price of eculizumab down, and the availability of new drugs that could equal eculizumab in safety and efficacy could still disrupt its market share.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.